Frans Plötz (Netherlands)

Tergooi Pediatrics

Author Of 1 Presentation

SYSTEMIC AND MUCOSAL HUMORAL IMMUNITY AGAINST SARS-COV-2 IN CHILDREN

Date
Thu, 12.05.2022
Session Time
10:00 - 11:30
Session Type
Oral Presentations Session
Room
BANQUETING HALL
Lecture Time
10:32 - 10:42

Abstract

Backgrounds:

Patients produce systemic and mucosal antibodies after SARS-CoV-2 infection. In the context of ongoing public health measures and vaccination programs, it is crucial to explore practical methods to monitor this humoral immunity. Following our earlier findings of heterogeneity in serum and saliva SARS-CoV-2 antibodies in 2020, we now describe antibody prevalence in serum and saliva of children one year after the beginning of the pandemic and explore associations.

Methods

We assessed SARS-CoV-2 antibody prevalence in serum and saliva of 223 children attending medical services in the Netherlands (irrespective of COVID-19 exposure) from May - October 2021. The cohort included vaccinated and unvaccinated children (< 18 years old) and was compared to 517 unvaccinated children from the April - October 2020 cohort. We measured SARS-CoV-2 spike- and nucleocapsid-specific IgG prevalence in serum and saliva.

Results:

Our cohort contained 75% unvaccinated children, 18% with a PCR-proven history of COVID-19, and a 1:1 male-female ratio. Antibody prevalence increased from 3-4% in both serum and saliva in 2020 to 38% (95% CI 31 - 45) in serum and 31% (95% CI 25 - 38) in saliva in 2021. Paired analysis (figure 1) showed positive titers in both serum and saliva in 53/196 (27%). Prevalence of spike and nucleocapsid-specific IgG was significantly lower in saliva compared to serum (P<0.05). Girls showed a higher prevalence of saliva antibodies as compared to boys (OR 2.26 corrected for age, vaccination status, comorbidity, positive PCR).

espid 2022 mw keuning - sarscov2 systemic and mucosal antibodies figure 1.jpg

Conclusions/Learning Points:

SARS-CoV-2 antibody prevalence in children increased in serum and saliva between 2020 and 2021 in the Netherlands. We observed lower SARS-CoV-2 antibody prevalence in saliva compared to serum, which should be taken into account when evaluating humoral immunity.

Hide

Poster Author Of 4 e-Posters

AS06.b. Neonatal sepsis
AS10.a. Decision support tools

PD145 - IMPROVING ACCESS TO THE NEONATAL EARLY-ONSET SEPSIS CALCULATOR: AN OPEN-SOURCE SCRIPT TO FACILITATE LOCAL USE, ELECTRONIC INTEGRATION AND FURTHER RESEARCH (ID 797)

Session Name
0730 - Poster Discussion Session 10: Congenital & Perinatal and Neonatal Infections (ID 10)
My link to connect
Topic: ESPID 2022 - E-Poster #797 Time: May 12, 2022 02:30 PM Athens Join Zoom Meeting https://us05web.zoom.us/j/84318430847?pwd=Z3hXR2ZFTmtSV0hudkl5VjlMbjY5Zz09 Meeting ID: 843 1843 0847 Passcode: q9ACTt
Availability (Date and Time)
Thursday, May 12, 2022 - 14.30-15.30 (Athens)